Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Research & Development: 2021-2024

Historic Research & Development for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $104.1 million.

  • Amylyx Pharmaceuticals' Research & Development fell 6.51% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.1 million, marking a year-over-year decrease of 26.98%. This contributed to the annual value of $104.1 million for FY2024, which is 18.80% down from last year.
  • Amylyx Pharmaceuticals' Research & Development amounted to $104.1 million in FY2024, which was down 18.80% from $128.2 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Research & Development ranged from a high of $128.2 million in FY2023 and a low of $44.0 million during FY2021.
  • In the last 3 years, Amylyx Pharmaceuticals' Research & Development had a median value of $104.1 million in 2024 and averaged $108.6 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 112.19% in 2022, then decreased by 18.80% in 2024.
  • Amylyx Pharmaceuticals' Research & Development (Yearly) stood at $44.0 million in 2021, then surged by 112.19% to $93.5 million in 2022, then spiked by 37.17% to $128.2 million in 2023, then dropped by 18.80% to $104.1 million in 2024.